Agitation and aggression commonly arise in people with Alzheimer's disease (AD) and other dementias. They are distressing for the individual and often confer risk to them and to others, as well as raising significant clinical challenges. This review outlines the current evidence for pharmacological and nonpharmacological approaches to the treatment of agitation and aggression in these patients.
INTRODUCTION
There are 35 million people with dementia worldwide [1] , and the most common cause is Alzheimer's disease. Dementia is a devastating condition, characterized by progressive cognitive and functional decline. Many people experience behavioral and psychological symptoms of dementia (BPSD), which include agitation and aggression. These symptoms occur in approximately 20% of people with Alzheimer's disease who are living in the community [2] and are more common in people living in care home settings, affecting 40-60% of these individuals [3] . Aggression is usually characterized by verbal insults and shouting, as well as physical manifestations, such as hitting, biting and throwing objects. They are particularly common during personal care. Other symptoms of agitation include restlessness and pacing, excessive fidgeting, motor activities associated with anxiety, such as hand wringing or following a carer around the home, and verbal signs of distress like shouting and screaming. In almost all individuals agitation and aggression significantly affect their daily lives [4] . They are often distressing for the person themselves [5] , as well as their caregivers, and result in increased care burden and the likelihood of depression in carers [6, 7] . BPSD are also associated with a reduced quality of life [8] and are commonly a main factor in the decision to move a person to an institutional care setting [9] .
Effective treatment of agitation and aggression in people with dementia is an essential element of providing high quality care and can impact significantly on key factors such as quality of life, wellbeing and care burden. There are some initial steps that are essential in order to provide the best treatment approach. A broad clinical assessment should always be conducted in order to direct the choice of therapy. The assessment may highlight specific issues for treatment, for example physical health problems, such as urinary tract infection or dental problems. Pain and dehydration are also common, particularly in people in the late stages of dementia. If these issues are not addressed they often lead to agitation and aggression, in part due to the person's inability to communicate their discomfort and unmet need. Pain is difficult to assess in people with dementia and is underdiagnosed, but better pain management does reduce agitation and aggression [10] . The clinical assessment should also include a medication review to highlight any existing prescriptions that may be exacerbating the BPSD. The assessment should then be used to decide on the most appropriate treatment approach, often with a combination of nonpharmacological and drug treatments, and based on the principles of person-centred care.
Nonpharmacological treatments
All guidance for treatment of agitation and aggression recommends nonpharmacological approaches as first-line treatment options. The exceptions to this are cases in which symptoms are causing significant risk or extreme distress [11] . People experiencing sporadic agitation that is not causing undue distress or risk often respond to simple psychological therapies. It can also be very helpful to consult the person's relatives or care staff to gain insight into the person's condition. Careful monitoring of symptoms with some simple approaches is often sufficient to address the underlying issues, avoiding the need for more intensive treatment. Cohen-Mansfield et al. [12, 13] have developed a series of practical nondrug interventions for the treatment of agitation and aggression within a care home setting, which are based on the principles of person-centred care and include a number of activities and approaches including structured social interaction and use of music and reminiscence based on the person's interests and history. A randomized controlled trial (RCT) of 167 people with BPSD reported improvement in agitation in 105 participants and a smaller study also found benefit to specific elements of agitation such as shouting when the approach was used for 6 weeks. Promotion of positive activities in people living in the community has also been shown to confer benefit in RCTs [14] .
In an effort to translate the Cohen-Mansfield [15] inventory into a tool that could be easily implemented in clinical and care home settings our group developed a Brief Psychosocial Therapy (BPST), which reduces the time and expertise level required of care staff. The BPST is framed around a daily social interaction with a care assistant, which lasts up to 30 min. The interaction is personalized for the individual and takes place with supervision from a therapist who has received training in the BPST approach. An open trial of this intervention reported an improvement in agitation in over 200 participants (seven points on the Cohen-Mansfield Agitation Inventory), although this result should be treated with a degree of caution as there was no control group for comparison. Nevertheless, the outcome supports the use of a structured nonpharmacological approach by professionals as a first-line treatment option for agitation and aggression, and emphasizes the value of treatment without the need for medication.
Although more severe and challenging agitation and aggression often requires pharmacological intervention, this level of BPSD does also respond to intense psychological approaches when tailored to the individual. The literature, including large case series and some small trials with robust design, supports the use of comprehensive person-centred interventions based on antecedent, behavior, consequence (ABC) charts and delivered by a clinical psychologist [16] .
A potentially valuable nonpharmacological alternative is also provided through effective staff training designed to develop a more comprehensive
KEY POINTS
Nonpharmacological approaches based on personcentred care combined with medical review should be the first-line approach for treatment of agitation and aggression in people with dementia.
Risperidone is the only antipsychotic recommended for short-term use in people with dementia but should be accompanied by close monitoring to reduce adverse events.
There is promising preliminary evidence to support potential benefit of memantine, carbamazepine, citalopram and prazosin in addressing BPSD.
Future development of treatments should consider the underlying biology of symptoms in order to provide targeted interventions.
skill set in care staff. Studies evaluating training that aims to improve management of BPSD and quality of care have reported mixed outcomes, with shorter-term studies suggesting that benefits are not sustained over the long term after the training period ends. However, more recently trials of intensive training packages and interventions have shown substantial benefit for up to 12 months. One RCT involving 347 care home residents reported significantly reduced prescribing of antipsychotic medication and no worsening of BPSD in homes where staff received training in person-centred care delivered by a health professional over 9 months [17] . Similar results have also been reported in a study in nine care homes evaluating a nursing home liaison service based on Cognitive Behavioural Therapy, delivered by an old-age psychiatrist and community psychiatric nurse [18] . Additional studies to support training interventions include a very high calibre three-arm cluster RCT of personcentred care augmented by Dementia Care Mapping in 15 care homes, which reported a significant reduction in agitation on the Cohen-Mansfield Agitation Inventory (standardized effect size Cohen's d >0.5 for both treatments) [19] .
Pharmacological treatments
A number of pharmacological agents have been proposed for the treatment of agitation and aggression, although many have a very limited evidence base to support their use. The most commonly used treatment is antipsychotic medication despite the known risk profile of these drugs.
Antipsychotics
The evidence regarding the use of antipsychotics for the treatment of agitation and aggression is summarized in Table 1 .
Typical antipsychotics, developed to treat schizophrenia in the 1950s and 1960s, were the first generation of this drug class. They began to be used frequently as an 'off-licence' treatment for BPSD in the 1970s although they were subsequently replaced by atypical antipsychotics in usual practice. Eleven RCTs, mostly small in size and over 4-12 weeks, have evaluated the impact of treatment with typical antipsychotics on agitation and shown a significant but modest improvement compared with placebo (59 versus 41%) although it should be noted that trials report a very high placebo response [20] . For context, a 30% improvement in standard BPSD scales is considered to be a good outcome in trials of this nature. The typical antipsychotic haloperidol holds the most comprehensive evidence base for treatment of BPSD, with four RCTs showing improvement in aggression [21] but no evidence for benefit in agitation. There is very little RCT literature on the value of other typical antipsychotics for treatment of these symptoms.
The potential benefit of these medications must be considered in the light of the numerous safety concerns associated with the use of typical antipsychotics in people with Alzheimer's disease. Adverse effects include parkinsonism [22] , dystonia, tardive dyskinesia, acceleration of cognitive decline and prolongation of the QTc interval on ECG, leading to added risk of cardiac arrhythmias. This effect has been reported with a number of typical antipsychotics, including thioridazine and droperidol [23] . Thioridazine, promazine and haloperidol were previously widely prescribed for people with dementia but since 2000 they have mostly been withdrawn due to these substantial safety concerns, particularly regarding the cardiac safety of thioridazine, and the overall side effect profile and the extremely high mortality risk. Prescription of haloperidol remains controversial, and is still recommended and widely used in some countries despite its established risk profile.
Atypical antipsychotics were developed for treatment of schizophrenia in the 1990s, and include risperidone, olanzapine, aripiprazole and quetiapine. They have mostly replaced typical antipsychotics for treatment of BPSD due to perceived improved tolerability, mostly due to their relatively improved safety profile in patients with schizophrenia bipolar affective disorders.
There is a more robust evidence base around the use of atypical antipsychotics to treat agitation and aggression in dementia. The literature includes 18 RCTs of treatment over 6-12 weeks in people with Alzheimer's disease [24, 25] . Risperidone holds the most encouraging profile of efficacy, with five RCTs reporting modest but significant improvement in aggression compared with placebo, with a larger effect size conferred by a dose of 2 mg per day. For example, a dose of 1 mg daily resulted in an effect of À0.84 points [95% confidence interval (CI) À1.28 to À0.40 points] on the BehavAD (Behavioral Pathology in Alzheimer Disease) rating scale, compared with À1.50 points (95% CI À2.05 to À0.95 points) with 2 mg daily, equating to a small treatment effect size (Cohen's d 0.2 at the optimal dose). Despite this effect on aggression, however, there is no consistent evidence of benefit of risperidone for the treatment of nonaggressive symptoms of agitation such as restlessness and shouting [24, 25] . For other atypical antipsychotics, aripiprazole has been shown to confer a similar level of improvement in aggression to that seen for risperidone, based on two published trials [25] , whereas evidence for olanzapine is conflicting. There is clear evidence that quetiapine is not effective. The evidence around other atypical antipsychotics is extremely limited [24] . Longer-term treatment with these medications is not supported by the literature, although there have been few trials into this use. Two RCTs, the Quetiapine and Rivastigmine for Agitation in Alzheimer's disease and the dementia antipsychotic withdrawal (DART) trials showed no benefit over 6 months. One further trial, Clinical Antipsychotic Trials of Intervention Effectiveness, also reported no improvement in the long term, although the study did indicate that discontinuation of antipsychotics due to perceived ineffectiveness over 9 months was less likely than placebo [26] .
Despite replacing typical antipsychotics due to a perceived improved safety profile, atypical antipsychotics are still associated with a significant number of adverse effects, including extrapyramidal symptoms, sedation, gait disturbances and falls. Tardive dyskinesia is less common than with typical antipsychotics, but a number of studies have highlighted Q-Tc prolongation as a concern [23]. A meta-analysis also reported the concerning frequency of respiratory and urinary tract infections and peripheral oedema in RCTs evaluating risperidone [24] . Anticholinergic effects of many atypical antipsychotics are also thought to increase the risk of delirium [22, 24] . These adverse effects are common and likely to be class effects, although this cannot be confirmed due to the lack of evidence for other atypical antipsychotics. Furthermore, more recent evidence has raised a serious concern regarding the increased risk of cerebrovascular events in people with Alzheimer's disease treated [24] and a trial of aripiprazole reported a similar increase in cerebrovascular events. Prescription event monitoring suggested that this is a class effect across atypical antipsychotics. There is also a significant increased mortality risk (OR 1.7) associated with atypical antipsychotics, which has resulted in a formal black box warning by the Food and Drug Administration [27] . A further independent systematic review of 15 RCTs of atypical antipsychotics confirmed the significant increased risk (OR 1.54) for all atypical antipsychotics [28] , and this is supported by the DART-AD trial, which reported increased mortality in patients prescribed agents in the long term [29] , and one further study [30] , which demonstrated an even greater excess of mortality. The most common cause of death was pneumonia [31 & ], with a high frequency of thromboembolic events (including stroke, deep vein thrombosis, pulmonary embolism and cardiac events) and an increase in sudden cardiac arrhythmias [31 & ]. It is likely that oversedation, dehydration and prolongation of QTc interval are key factors in these mortalities. It is particularly important to note that many of these risk profiles could be significantly reduced through closer monitoring and implementation of earlier interventions and preventive approaches.
It has been suggested that response to treatment with antipsychotics may be influenced by genetic profile. The T allele of the 5HT2A T102C polymorphism appears to dictate a worse response to risperidone than the C allele [32] and a recent genetic association RCT [33] reported the influence of the length of the polymorphism in the serotonin transporter gene (5-HTTLPR) in early treatment response, although these findings are preliminary. This emerging evidence also emphasizes the value of monitoring and individualization of treatment, and the potential for pharmacogenetics to influence treatment decisions.
Taken together, the best evidence for the pharmacological treatment of aggression with an antipsychotic is for risperidone. However, it is recommended that treatment is only undertaken in cases in which there is extreme distress or risk, in which other approaches have not been successful, and in which prescriptions do not exceed 12 weeks. Individuals should also be carefully monitored in order to reduce adverse effects. This is consistent with best practice guidelines. Long-term prescribing of antipsychotics is not associated with significant benefit and results in a greatly increased risk of severe adverse events, including death. This should therefore only be considered as a last resort when all other treatment approaches have failed. Longterm prescriptions should also be accompanied by trials of withdrawal. Although there is significant pressure on the prescribing community to reduce antipsychotic prescriptions, it is important that this is undertaken within a framework of overall improved prevention and management of BPSD including assessment of underlying clinical issues and the use of alternative nonpharmacological approaches. It is accepted that there will always be a small group of individuals for whom carefully administered short-term prescriptions of antipsychotics will be the most appropriate treatment option.
Analgesics
Pain is a common underlying cause of BPSD, particularly agitation and aggression. Pain arises frequently in older adults and represents a significant unmet need in people with dementia who are unable to communicate their discomfort. Identification and effective treatment of pain can therefore be effective in addressing the underlying issue and resulting in improvement of agitation and aggression. A recent cluster RCT compared stepped analgesia with usual care over 8 weeks in 352 people with Alzheimer's disease experiencing significant agitation. The first treatment was 3 g per day dosage of paracetamol, with the majority of participants in the active treatment arm remaining on this level of the stepped care protocol throughout the study. A significant seven-point improvement was seen in the Cohen-Mansfield Agitation Inventory in comparison to the control group. The improvement in agitation was also significantly correlated with improvement in pain [34 & ]. Many of the individuals had low levels of pain, emphasizing that treating even minor, low-level pain may confer considerable benefit as part of the management of agitation.
Cholinesterase inhibitors
There is some limited evidence to suggest that ChEIs may improve overall BPSD, although the advantage over placebo is modest [35] . A randomized withdrawal study also provides some support for ChEIs, reporting that withdrawal of donepezil resulted in worsening of BPSD [36] . However, two RCTs evaluating donepezil and rivastigmine over 12 and 24 weeks, respectively, for the treatment of clinically significant agitation showed no treatment benefit [37, 38] , indicating that ChEIs do not appear to be useful in the management of acute agitation. An RCT of galanthamine indicated a possible effect in delaying emergence of BPSD following treatment over 5 months [39] . However, these effects are not specifically for agitation or aggression. When considering the overall BPSD spectrum, ChEIs have the best evidence for their effect on depression and dysphoria, apathy and indifference, and anxiety [40] , and there does not appear to be specific benefit in the treatment of agitation or aggression.
Memantine
There is some encouraging evidence that indicates that memantine may be valuable in the treatment of mild-to-moderate irritability, agitation or aggression for up to 6 months [41] [42] [43] [44] . This is based on literature including individual studies, metaanalyses, and pooled analyses. However, it should be noted that as yet there is little RCT evidence to support these indications. One recent trial, the Memantine for Agitation in Alzheimer's Dementia trial, did not observe any improvement in agitation in 153 people treated with memantine or placebo over 6 and 12 weeks as measured by the Cohen-Mansfield Agitation Inventory. The study did report benefit on the overall Neuropsychiatric Inventory score, but not on the Clinical Global Impression of Change, indicating that any benefits were not of sufficient magnitude to support recommendation of memantine for clinical use in treatment of agitation and aggression in Alzheimer's disease [45 && ]. In contrast to this, a post-hoc analysis [44] and a recent RCT [46 & ] have suggested that memantine may be of value in reducing the emergence of overall BPSD. The RCT, the Donezepil and Memantine in Moderate to Severe Alzheimer's Disease trial, reported a 5.5-point significant advantage favouring memantine over placebo at 6-month follow-up on the total Neuropsychiatric Inventory [46 & ]. The current evidence is contradictory, but indicates that memantine may confer benefit in the prevention and treatment of mild-to-moderate agitation and aggression. It is hoped that ongoing RCTs will further clarify the potential role of memantine in treating agitation and aggression in patients with Alzheimer's disease in the near future.
Antidepressants
Evidence for the use of antidepressants to address agitation and aggression is limited. A 17-day trial in psychiatric inpatients with severe BPSD related to Alzheimer's disease [47] reported improvement in symptoms following treatment with citalopram compared with placebo, with the greatest effect on agitation or aggression. A more recent trial reported that citalopram resulted in a comparable improvement to risperidone, with a particularly improved effect on agitation and far better tolerability than the antipsychotic [48] . RCTs of sertraline [49] and trazadone [50] have been less promising.
Anticonvulsants
Initial RCTs of anticonvulsants have indicated some promise, with two small parallel-group trials of carbamazepine over 6 weeks or less showing some potential benefit [51, 52] . A meta-analysis of the two trials [40] reported significant improvement on both the Brief Psychiatric Rating Scale (mean difference À5.5; 95% CI, À8.5 to À2.5) and on Clinical Global Improvement (OR, 10.2; 95% CI, 3.1-33.1), and both studies showed good tolerability in people with Alzheimer's disease. In contrast, valproate has not shown benefit for treatment of BPSD [53] .
Other treatments
As this field moves forward, an important aspect of study focus will be to incorporate knowledge of the underlying biology of symptoms such as agitation and aggression to target treatment more effectively. For example, post-mortem studies have established the relationship between altered adrenoceptors and agitation and aggression in people with Alzheimer's disease [54] , and this has been translated into promising findings in a preliminary, small RCT of the a-adrenoceptor blocker prazosin in treating BPSD [55] . Targeted drug development based upon the principles of evidence-based experimental medicine is more likely to lead to the development of effective therapies.
Existing clinical guidance
A best practice guide for health professionals to support the prevention and management of BPSD, including agitation and aggression, has been published by Alzheimer's Society (United Kingdom) and the UK Department of Health (www.alzheimers. org.uk/bpsdguide; recently published best practice guide on the management of BPSD, incorporating up-to-date evidence and providing a practical resource for health professionals working with people with dementia). The evidence-based tool provides practical advice and a structured framework for physicians to use to support their decision-making when addressing BPSD. It also outlines measures to be taken with all people with dementia to improve reduction of emergence of BPSD. The toolkit is based on the principles of person-centred care, including options for structured medical review and nonpharmacological treatment approaches, as well as recommendations for pharmacological treatment when other alternatives have been unsuccessful. A key focus of the toolkit is also in supporting professionals to discontinue antipsychotic prescriptions and improve monitoring in cases in which prescriptions are deemed necessary. The guide provides medical care plans and assessment tools to support decisions regarding treatment, including the prescription and discontinuation of antipsychotics, and effective monitoring and review. The guide is available for professionals to use in clinical practice, although it is not designed for use in acute hospital settings. It is available as a download from Alzheimer's Society (www.alzheimers.org.uk/bpsdguide) and is endorsed and promoted by the Department of Health, Royal College of General Practitioners and Royal College of Psychiatrists as a key tool in the drive to reduce antipsychotic drugs in people with dementia.
CONCLUSION
Agitation and aggression are frequent and distressing symptoms in people with Alzheimer's disease. Implementing the best currently available evidence to optimize well-tolerated and effective management is imperative, including medical treatment of underlying conditions and pain, routinely implementing effective nonpharmacological treatment and the judicious short-term use of antipsychotics when appropriate. To move the field forward, considerably more focus is needed to evaluate potential pharmacological alternatives in adequately powered RCTs, including better targeting of treatment to underlying biology. It is essential that clinicians are supported in their decisionmaking around treatment approaches and that prevention and treatment of agitation and aggression are effected within a framework of person-centred care that involves the person, their family and care staff.
